Canadians living
with schizophrenia
deserve to have their
needs met.
Improved preventative measures are needed to ensure that people living with schizophrenia can reduce relapse while reintegrating into the community after being discharged from the hospital.
To manage symptoms, access to things like talk therapy, peer support, psychological and social programs, and community services are necessary. These supports aren’t easily accessible to people living in rural or Indigenous populations, those who are unhoused, or those who don’t have designated family doctors or psychiatrists.
There are many possible reasons why it could be difficult for people with schizophrenia to adhere to treatment, such as anxiety around side effects, an inadequate follow-up plan from their care team, or a lack of insight into the benefits of treatment.
The meeting leading to this expert consensus report was sponsored by Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. This report represents a summary of the discussions that took place during the meeting. Discussions were solely based on scientific evidence and expert opinion. Discussions and recommendations presented during the meeting were supported by the company, and all multidisciplinary participants were independent experts in their respective fields. Medical writing was provided by Myelin & Associates and funded by Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.
This initiative was supported by Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.
